Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Apabetalone by Resverlogix for Post-Acute Sequelae of COVID 2019 (PASC or Long COVID): Likelihood of Approval
Apabetalone is under clinical development by Resverlogix and currently in Phase I for Post-Acute Sequelae of COVID 2019 (PASC or...